Trials / Completed
CompletedNCT02239081
A Safety and Tolerability Study of CTP-730 in Healthy Volunteers
A Randomized, Double-blind, Single Ascending Dose, Safety, Tolerability, Pharmacokinetics Study of CTP-730 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Concert Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, single center, single-ascending dose, randomized study
Detailed description
Following a Screening period of up to 21 days, eight (8) subjects in each cohort, 6 subjects randomized to CTP-730 and 2 subjects randomized to placebo, will be admitted to the clinical research unit (CRU) on the evening before dosing and remain sequestered at the study site until after the last inpatient blood sample is collected at 48 hours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CTP-730 | |
| DRUG | Placebo for CTP-730 |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-01-01
- Completion
- 2015-05-01
- First posted
- 2014-09-12
- Last updated
- 2015-05-29
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT02239081. Inclusion in this directory is not an endorsement.